Kura Oncology (KURA)
(Delayed Data from NSDQ)
$6.03 USD
-0.33 (-5.19%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $6.04 +0.01 (0.17%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KURA 6.03 -0.33(-5.19%)
Will KURA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KURA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KURA
Is the Options Market Predicting a Spike in Kura Oncology Stock?
KURA Stock Rises More Than 15% This Past Week: Here's Why
KURA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates
Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates
Other News for KURA
Kura Oncology (KURA) Grants Inducement Awards to New Employees
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KURA Stock News
Kura Oncology reports inducement grants under Nasdaq listing rule
Kura Oncology to Report Second Quarter 2025 Financial Results | KURA Stock News
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KURA Stock News